FR16C0011I1 - - Google Patents
Info
- Publication number
- FR16C0011I1 FR16C0011I1 FR16C0011C FR16C0011I1 FR 16C0011 I1 FR16C0011 I1 FR 16C0011I1 FR 16C0011 C FR16C0011 C FR 16C0011C FR 16C0011 I1 FR16C0011 I1 FR 16C0011I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46960003P | 2003-05-06 | 2003-05-06 | |
US48796403P | 2003-07-17 | 2003-07-17 | |
US53920704P | 2004-01-26 | 2004-01-26 | |
PCT/US2004/014064 WO2005001025A2 (en) | 2003-05-06 | 2004-05-06 | Immunoglobulin chimeric monomer-dimer hybrids |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0011I1 true FR16C0011I1 (nl) | 2016-04-22 |
FR16C0011I2 FR16C0011I2 (fr) | 2017-04-14 |
Family
ID=33458764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0011C Active FR16C0011I2 (fr) | 2003-05-06 | 2016-03-15 | Hybrides monomeres/dimeres chimeriques d'immunoglobuline |
Country Status (28)
Country | Link |
---|---|
US (13) | US7404956B2 (nl) |
EP (7) | EP1625209B1 (nl) |
JP (6) | JP5091480B2 (nl) |
CN (3) | CN104448003B (nl) |
AT (1) | ATE446307T1 (nl) |
AU (1) | AU2004252422B2 (nl) |
BE (1) | BE2016C015I2 (nl) |
BR (2) | BR122019011535B1 (nl) |
CA (1) | CA2522590C (nl) |
CY (4) | CY1114639T1 (nl) |
DE (1) | DE602004023724D1 (nl) |
DK (4) | DK2357196T3 (nl) |
EA (1) | EA012566B1 (nl) |
ES (3) | ES2579938T3 (nl) |
FR (1) | FR16C0011I2 (nl) |
HK (2) | HK1159649A1 (nl) |
HU (4) | HUE030293T2 (nl) |
IL (2) | IL171779A (nl) |
LT (2) | LTC1625209I2 (nl) |
LU (1) | LU92991I2 (nl) |
NL (1) | NL300799I2 (nl) |
NO (5) | NO339539B1 (nl) |
PL (3) | PL1625209T3 (nl) |
PT (3) | PT2361932T (nl) |
SI (4) | SI2361932T1 (nl) |
TW (1) | TWI353991B (nl) |
UA (1) | UA95436C2 (nl) |
WO (2) | WO2004101739A2 (nl) |
Families Citing this family (377)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
PL2077121T3 (pl) | 2003-05-06 | 2011-07-29 | Syntonix Pharmaceuticals Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20050037947A1 (en) * | 2003-05-06 | 2005-02-17 | Bitonti Alan J. | Inhibition of drug binding to serum albumin |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
ES2372495T3 (es) * | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CN101184771A (zh) * | 2005-05-26 | 2008-05-21 | 先灵公司 | 干扰素-IgG融合体 |
ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
LT1917276T (lt) | 2005-08-26 | 2018-05-25 | Ares Trading S.A. | Glikozilinto interferono beta gavimo būdas |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
US8153598B2 (en) * | 2005-10-19 | 2012-04-10 | Intrexon Corporation | PKD ligands and polynucleotides encoding PKD ligands |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CN102827287B (zh) * | 2005-10-31 | 2015-08-12 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
WO2007065918A2 (en) | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
EP2650305B1 (en) * | 2006-03-24 | 2024-05-08 | Bioverativ Therapeutics Inc. | PC5 as a factor IX propeptide processing enzyme |
KR101492422B1 (ko) * | 2006-04-11 | 2015-02-12 | 체에스엘 베링 게엠베하 | 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법 |
MX2008014685A (es) | 2006-05-24 | 2008-11-27 | Novo Nordisk Healthcare Ag | Analogos de factor ix con semivida prolongada in vivo. |
JP5800458B2 (ja) * | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US20100021379A1 (en) * | 2006-06-29 | 2010-01-28 | The Regents Of The University Of California | Chemical Antibodies for Immunotherapy and Imaging |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
WO2008019817A1 (en) * | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
WO2008051326A2 (en) * | 2006-08-21 | 2008-05-02 | President And Fellows Of Harvard College | Identification of contactins and l1- cams as ligands for the amyloid precursor protein |
WO2008025748A1 (en) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
AU2007291282B2 (en) * | 2006-08-28 | 2011-10-20 | Ares Trading S.A. | Process for the purification of Fc-fusion proteins |
WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
PE20081140A1 (es) * | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
SG176476A1 (en) * | 2006-11-02 | 2011-12-29 | Daniel J Capon | Hybrid immunoglobulins with moving parts |
AU2007338298B2 (en) | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP2109457B1 (en) * | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
WO2008124406A2 (en) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Methods of treatment using glycopegylated g-csf |
CA2687141C (en) * | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP2170919B8 (en) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
TWI554520B (zh) * | 2007-07-20 | 2016-10-21 | 諾華健控股公司 | 在活體中具有延長之半生期以及提高之紅血球生成活性的重組人類紅血球生成素(epo)-fc融合蛋白 |
US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
US8906844B2 (en) * | 2007-08-09 | 2014-12-09 | Biogen Idec Hemophilia Inc. | Immunomodulatory peptides |
CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
US20100260751A1 (en) * | 2007-09-28 | 2010-10-14 | Raju T Shantha | Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases |
US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
WO2009053368A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
MX2010004298A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
WO2009064838A1 (en) | 2007-11-15 | 2009-05-22 | Amgen, Inc. | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | FC variants with modified binding to FCRN |
CN102089320B (zh) * | 2008-01-24 | 2015-11-25 | 埃斯佩兰斯医药公司 | 溶解结构域融合构建体及其制备和使用方法 |
EP2574628B1 (en) | 2008-01-25 | 2015-05-20 | Amgen Inc. | Ferroportin antibodies and methods of use |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
EA020326B9 (ru) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
JP5792621B2 (ja) | 2008-09-26 | 2015-10-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | frizzled結合剤およびその使用 |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
WO2010048313A2 (en) * | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
CN102215869B (zh) | 2008-11-13 | 2015-05-13 | 通用医疗公司 | 用于通过调整bmp-6来调节铁稳态的方法和组合物 |
CA2742817A1 (en) | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
JP5755566B2 (ja) | 2008-12-19 | 2015-07-29 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
CN102448482A (zh) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法 |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2417156B1 (en) * | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
CN102405230A (zh) | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | 具有修饰的FcRn结合位点的抗体融合蛋白 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CN104945509A (zh) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
AU2010310457B2 (en) | 2009-10-23 | 2015-07-02 | Amgen Inc. | Vial adapter and system |
WO2011060242A2 (en) | 2009-11-13 | 2011-05-19 | Talecris Biotherapeutics, Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
SG181130A1 (en) * | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
WO2011143209A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
KR20180037303A (ko) | 2010-06-07 | 2018-04-11 | 암젠 인크 | 약물 전달 장치 |
EP2582719B1 (en) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
CN103179979A (zh) | 2010-06-24 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
US8946147B2 (en) | 2010-06-24 | 2015-02-03 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
EP2673294B1 (en) | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
CA2829037C (en) | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
CA2833748C (en) | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US10683362B2 (en) | 2011-05-06 | 2020-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
WO2012170969A2 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
LT2723367T (lt) | 2011-06-22 | 2017-08-25 | Indiana University Research And Technology Corporation | Bendri gliukagono/glp-1 receptoriaus agonistai |
DK3513804T3 (da) | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
CA2841185C (en) | 2011-07-22 | 2021-05-25 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
JP6108630B2 (ja) | 2011-10-06 | 2017-04-05 | ハンミ サイエンス カンパニー リミテッドHanmi Science Co.,Ltd. | 血液凝固因子VII及びVIIa誘導体、それらを含む結合体及び複合体、並びにそれらの使用 |
PT3045189T (pt) | 2011-10-14 | 2018-07-23 | Amgen Inc | Injetor e método de montagem |
EP2784080B1 (en) * | 2011-10-31 | 2019-12-18 | Shimadzu Corporation | Peptide-hinge-free flexible antibody-like molecule |
BR112014007124A2 (pt) | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
JP6392123B2 (ja) | 2011-12-20 | 2018-09-19 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 糖尿病治療のためのctp系インスリンアナローグ |
MY201293A (en) | 2012-01-12 | 2024-02-15 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
CA2863329C (en) | 2012-01-12 | 2023-01-03 | Biogen Idec Ma Inc. | Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
WO2013119966A2 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第viii因子タンパク質 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
JP2015516078A (ja) * | 2012-05-03 | 2015-06-04 | メディミューン,エルエルシー | 試料成分の分析方法 |
EP2858659B1 (en) | 2012-06-08 | 2019-12-25 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
TW201402611A (zh) | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之fc效應子功能之腸促胰島素受體配體多肽fc區融合多肽及結合物 |
BR112014031671A2 (pt) | 2012-06-21 | 2018-08-07 | Hoffmann La Roche | análogos de glucagon exibindo atividade de receptor gip |
AR091477A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
JP6203838B2 (ja) | 2012-06-27 | 2017-09-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用 |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
DK2882450T3 (da) | 2012-07-11 | 2020-02-24 | Bioverativ Therapeutics Inc | Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf |
CN104640562A (zh) * | 2012-07-13 | 2015-05-20 | 酵活有限公司 | 包含抗-cd3构建体的双特异性不对称异二聚体 |
US10001495B2 (en) | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
WO2014020056A1 (en) | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
JP2015536933A (ja) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法 |
US20150266944A1 (en) | 2012-10-30 | 2015-09-24 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
MX2015006343A (es) | 2012-11-21 | 2015-10-05 | Amgen Inc | Dispositivo de administracion de farmacos. |
CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
WO2014121196A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
EP2964255B1 (en) | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
US20160017017A1 (en) | 2013-03-11 | 2016-01-21 | Novo Nordisk Healthcare Ag | Growth Hormone Compounds |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3666283B1 (en) | 2013-03-15 | 2022-06-08 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
JP6602746B2 (ja) * | 2013-03-15 | 2019-11-06 | カポン、ダニエル・ジェイ. | 非ペプチジル結合を含むハイブリッド免疫グロブリン |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
ES2695166T3 (es) | 2013-03-15 | 2019-01-02 | Intrinsic Lifesciences Llc | Anticuerpos antihepcidina y usos de los mismos |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
KR102287687B1 (ko) | 2013-03-22 | 2021-08-06 | 암젠 인크 | 인젝터 및 조립 방법 |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
EP3013366B1 (en) | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
WO2015021423A2 (en) | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
CN103599527A (zh) * | 2013-08-16 | 2014-02-26 | 安源生物科技(上海)有限公司 | 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物 |
US9388430B2 (en) * | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
WO2015048330A2 (en) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | On-column viral inactivation methods |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3055329B1 (en) | 2013-10-11 | 2018-06-13 | F. Hoffmann-La Roche AG | Multispecific domain exchanged common variable light chain antibodies |
JP7086520B2 (ja) | 2013-10-24 | 2022-06-20 | アムジエン・インコーポレーテツド | インジェクター及び組み立ての方法 |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
CA2930243A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
MX2016006572A (es) | 2013-11-27 | 2016-12-09 | Zymeworks Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
ES2967617T3 (es) | 2013-12-06 | 2024-05-03 | Bioverativ Therapeutics Inc | Herramientas de farmacocinética poblacional y sus usos |
WO2015095684A1 (en) | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
JP2017500017A (ja) | 2013-12-20 | 2017-01-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
NZ722391A (en) | 2014-02-04 | 2022-12-23 | Biogen Ma Inc | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
SI3701971T1 (sl) * | 2014-03-14 | 2023-01-31 | Biomolecular Holdings LLC, | Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo |
RU2711485C2 (ru) * | 2014-04-11 | 2020-01-17 | МЕДИММЬЮН, ЭлЭлСи | Конъюгированные соединения, содержащие сконструированные с цистеином антитела |
WO2015171777A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
KR20230037063A (ko) | 2014-06-03 | 2023-03-15 | 암겐 인코포레이티드 | 제어 가능한 약물 전달 시스템 및 사용 방법 |
AU2015276089B2 (en) | 2014-06-18 | 2021-03-18 | Csl Behring Gmbh | Therapy using a Factor XII inhibitor in a neurotraumatic disorder |
EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
JP2018500272A (ja) | 2014-09-26 | 2018-01-11 | バイエル ファーマ アクチエンゲゼルシャフト | 安定化アドレノメデュリン誘導体およびその使用 |
CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
WO2016061220A2 (en) | 2014-10-14 | 2016-04-21 | Amgen Inc. | Drug injection device with visual and audio indicators |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
CN106999602B (zh) * | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
EP3556411B1 (en) | 2015-02-17 | 2021-06-30 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
CA2980757A1 (en) * | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
SG10201910896UA (en) | 2015-05-22 | 2020-01-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
WO2016193380A1 (en) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
CN113372443A (zh) | 2015-09-18 | 2021-09-10 | 中外制药株式会社 | Il-8-结合抗体及其应用 |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
WO2017070167A1 (en) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
CN105384828B (zh) * | 2015-12-18 | 2019-06-21 | 中国科学技术大学 | 长效干扰素-α及其改造方法 |
EP3184149A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Soluble glycoprotein v for treating thrombotic diseases |
RU2647769C2 (ru) * | 2015-12-30 | 2018-03-19 | Закрытое Акционерное Общество "Биокад" | Химерный улучшенный рекомбинантный фактор VIII |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
KR20180098404A (ko) | 2016-01-07 | 2018-09-03 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 돌연변이된 폰 빌레브란트 인자 |
SG10201912498YA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated truncated von willebrand factor |
EP3402823A4 (en) * | 2016-01-11 | 2019-09-18 | Inhibrx, Inc. | MULTIVALENT AND MULTISPECIFIC 41BB BINDING FUSION PROTEINS |
SI3411478T1 (sl) | 2016-02-01 | 2022-10-28 | Bioverativ Therapeutics Inc. | Optimirani geni dejavnika VIII |
CN106397599B (zh) * | 2016-02-23 | 2020-08-07 | 上海交通大学 | 二价双特异性抗体杂交蛋白的表达和制备方法 |
CN106397598B (zh) * | 2016-02-23 | 2020-07-14 | 上海交通大学 | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 |
EP3429663B1 (en) | 2016-03-15 | 2020-07-15 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
CN109071629A (zh) | 2016-04-06 | 2018-12-21 | 杰特有限公司 | 治疗动脉粥样硬化的方法 |
WO2017181145A1 (en) * | 2016-04-14 | 2017-10-19 | Iconic Therapeutics, Inc. | Compositions and methods for treating disorders associated with νeοvascularization |
CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
WO2017191817A1 (ja) | 2016-05-02 | 2017-11-09 | 味の素株式会社 | アジド基含有Fcタンパク質 |
WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
AU2017268198C1 (en) | 2016-05-16 | 2020-11-26 | Takeda Pharmaceutical Company Limited | Anti-Factor IX Padua antibodies |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3519431A1 (en) | 2016-09-28 | 2019-08-07 | Cohbar Inc. | Therapeutic mots-c related peptides |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
AU2017358861B2 (en) | 2016-11-11 | 2022-02-17 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
EP3538134B1 (en) | 2016-11-11 | 2021-12-29 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
EP3573641A4 (en) * | 2017-01-25 | 2020-11-11 | Iconic Therapeutics, Inc. | TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
WO2018156892A1 (en) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
SG11201908058UA (en) | 2017-03-07 | 2019-09-27 | Amgen Inc | Needle insertion by overpressure |
SG11201908062QA (en) | 2017-03-09 | 2019-09-27 | Amgen Inc | Insertion mechanism for drug delivery device |
CN110520152A (zh) | 2017-03-14 | 2019-11-29 | 俄亥俄州创新基金会 | 与靶向组织因子的igg3免疫缀合物有关的方法和组合物 |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
CN110505885A (zh) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
US20190078160A1 (en) * | 2017-04-21 | 2019-03-14 | Genentech, Inc. | Use of klk5 antagonists for treatment of a disease |
WO2018207023A2 (en) * | 2017-05-10 | 2018-11-15 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
US11541183B2 (en) | 2017-06-22 | 2023-01-03 | Amgen Inc. | Device activation impact/shock reduction |
WO2018234518A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ |
CA3063921A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
US20210163986A1 (en) | 2017-08-09 | 2021-06-03 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | PEPTIDE INHIBITORS OF TAU AGGREGATION |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
AU2018364933B2 (en) | 2017-11-10 | 2024-01-25 | Amgen Inc. | Plungers for drug delivery devices |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
JP7370969B2 (ja) | 2017-11-16 | 2023-10-30 | アムジエン・インコーポレーテツド | 薬物送達デバイスの扉ラッチ機構 |
JP7002927B2 (ja) | 2017-11-22 | 2022-01-20 | 本田技研工業株式会社 | 駆動軸配置構造 |
AU2019209428A1 (en) | 2018-01-22 | 2020-07-30 | Endocyte, Inc. | Methods of use for CAR T cells |
SG11202007114VA (en) | 2018-02-01 | 2020-08-28 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii |
MX2020009975A (es) | 2018-03-28 | 2020-10-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso. |
CU24554B1 (es) | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
JP2021523878A (ja) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病aを処置する方法 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
WO2020010117A2 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Fgf21 formulations |
MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3108799A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
US20210228811A1 (en) | 2018-09-28 | 2021-07-29 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CN112805048B (zh) | 2018-10-02 | 2023-09-22 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
CN109439679A (zh) * | 2018-10-09 | 2019-03-08 | 上海市儿童医院 | 一种高活性重组人凝血因子ix融合蛋白及其制备方法 |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
CA3113076A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
JP2022518814A (ja) | 2019-01-28 | 2022-03-16 | コーバー、インコーポレイテッド | 治療用ペプチド |
AU2020242945A1 (en) | 2019-03-19 | 2021-10-14 | CSL Innovation Pty Ltd | Factor IX variants and uses thereof in therapy |
CN114008069A (zh) | 2019-04-17 | 2022-02-01 | 科迪亚克生物科学公司 | 外来体和aav的组合物 |
WO2020219482A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
SG11202112117TA (en) | 2019-05-17 | 2021-12-30 | Univ Zuerich | Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke |
JP2022537369A (ja) | 2019-06-18 | 2022-08-25 | バイエル アクチェンゲゼルシャフト | 長期安定化のためのアドレノメデュリン-類似体およびその使用 |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
PE20230036A1 (es) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | Variantes de progranulina |
US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CA3198740A1 (en) | 2020-11-20 | 2022-05-27 | John Roberts | Method for treating antibody-mediated rejection |
EP4284407A1 (en) | 2021-02-01 | 2023-12-06 | CSL Behring AG | Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke |
CA3217518A1 (en) | 2021-05-07 | 2022-11-10 | Rebecca Butcher | Expression system for producing a recombinant haptoglobin (hp) beta chain |
CN117320964A (zh) | 2021-05-21 | 2023-12-29 | 美国安进公司 | 优化药物容器的灌装方案的方法 |
WO2024047219A1 (en) | 2022-09-02 | 2024-03-07 | Csl Behring Ag | Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (312)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US660843A (en) * | 1900-05-16 | 1900-10-30 | Rebecca Coyle | Nursing-gown. |
US786376A (en) | 1902-05-15 | 1905-04-04 | Fischer Motor Vehicle Company | Electrogasolene-vehicle. |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
US5189015A (en) | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
US5077204A (en) | 1984-06-21 | 1991-12-31 | Chiron Corporation | Yeast endopeptidase for basic amino-acid site cleavage, preparation and use |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US4889919A (en) | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
DK525384D0 (da) * | 1984-11-05 | 1984-11-05 | Nordisk Insulinlab | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
ATE87663T1 (de) | 1986-01-03 | 1993-04-15 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ- proteinen. |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
ATE143052T1 (de) | 1986-07-07 | 1996-10-15 | Centocor Inc | Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
PT89484B (pt) * | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
JP2643968B2 (ja) * | 1988-02-03 | 1997-08-25 | サントリー株式会社 | Kex2エンドプロテアーゼ及びその製造方法 |
US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2641468A1 (fr) * | 1989-01-11 | 1990-07-13 | Merieux Inst | Anticorps chimeriques anti-recepteur de l'interleukine-2 humaine, leur preparation et compositions pharmaceutiques les contenant |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
DK0474744T3 (da) | 1989-05-22 | 1994-11-21 | Zymogenetics Inc | PDGF-alfa-receptor |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
EP0415622B1 (en) | 1989-08-21 | 1994-01-05 | Ngk Insulators, Ltd. | Recording head including electrode supporting substrate having thin-walled contact end portion, and substrate reinforcing layer |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
DE59010908D1 (de) * | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
US5935815A (en) | 1989-10-25 | 1999-08-10 | Katholieke Universiteit Leuven | Process for micro biological production of proteins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
US20030064480A1 (en) | 1990-06-28 | 2003-04-03 | Leander Lauffer | Fusion proteins with immunoglobulin portions, the preparation and use thereof |
ATE309376T1 (de) | 1990-06-28 | 2005-11-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
WO1992009698A1 (en) | 1990-11-26 | 1992-06-11 | Genetics Institute, Inc. | Expression of pace in host cells and methods of use thereof |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
EP0563214A4 (en) * | 1990-12-04 | 1994-08-17 | Wistar Inst | Bifunctional antibodies and method of preparing same |
US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
JPH06506600A (ja) | 1991-04-19 | 1994-07-28 | シェリング・コーポレーション | ヒトインターロイキン 3 レセプターのサブユニット |
JPH06508133A (ja) * | 1991-05-31 | 1994-09-14 | ジェネンテク,インコーポレイテッド | Hivに関連した免疫性の血小板減少性紫斑病の治療 |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5346991A (en) | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5454933A (en) * | 1991-12-16 | 1995-10-03 | Exxon Research And Engineering Company | Deep desulfurization of distillate fuels |
ATE151113T1 (de) * | 1992-01-23 | 1997-04-15 | Merck Patent Gmbh | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス,インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
WO1994005328A1 (en) | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibition of tumor metastasis via neutralization of tissue factor function |
GB2270845B (en) | 1992-09-24 | 1996-07-10 | Smiths Ind Med Syst Inc | Suction catheter assemblies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
US5648446A (en) * | 1993-02-24 | 1997-07-15 | Mitsui Toatsu Chemicals, Inc. | Diguanamines and preparation process, derivatives and use thereof |
WO1994028017A1 (en) | 1993-06-01 | 1994-12-08 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US6518013B1 (en) * | 1993-06-07 | 2003-02-11 | Trimeris, Inc. | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
US6310180B1 (en) * | 1993-06-21 | 2001-10-30 | Vanderbilt University | Method for synthesis of proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
KR950003279A (ko) | 1993-07-29 | 1995-02-16 | 고사이 아끼오 | 플루오로알칸 카르복사미드 유도체의 제조방법 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
PT771216E (pt) | 1994-07-11 | 2001-07-31 | Scripps Research Inst | Metodos e composicoes para a coagulacao especifica da vasculatura tumoral |
WO1996010585A1 (en) * | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US5596080A (en) * | 1994-10-03 | 1997-01-21 | E. I. Du Pont De Nemours And Company | Crosslinking processes/agents for zein |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
DK1323346T3 (da) * | 1995-01-17 | 2006-10-30 | Brigham & Womens Hospital | Receptorspecifik transport af immunogener gennem epitelet |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5591573A (en) * | 1995-04-10 | 1997-01-07 | Alpha Therapeutic Corporation | Method and system for testing blood samples |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5579277A (en) * | 1995-05-01 | 1996-11-26 | Apple Computer, Inc. | System and method for interleaving memory banks |
US6184344B1 (en) * | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
KR100571215B1 (ko) * | 1995-06-07 | 2006-10-24 | 트라이머리스 인코퍼레이티드 | 복합적인치료요법을이용한hiv와다른바이러스감염의치료 |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5840529A (en) | 1995-08-02 | 1998-11-24 | Clinical Research Institute Of Montreal | Mammalian pro-hormone convertase |
EP0848755B2 (en) | 1995-09-08 | 2011-02-09 | Genentech, Inc. | Vegf-related protein |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
US20030026779A1 (en) | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2198968C (en) * | 1996-03-04 | 2010-02-09 | Toyofumi Masuda | Process for production of secretory kex2 derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
ATE465257T1 (de) | 1996-07-03 | 2010-05-15 | Genentech Inc | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen |
CA2203745A1 (en) | 1996-07-26 | 1998-01-26 | Robert Day | Pro-protein converting enzyme |
JP2001506967A (ja) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法 |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
EP2314695A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
KR100565883B1 (ko) | 1997-01-22 | 2006-03-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 응고 및 종양 치료용 조직 인자 방법 및 조성물 |
TW502011B (en) * | 1997-02-05 | 2002-09-11 | Ajinomoto Kk | Process for producing n-long-chain acyl acidic amino acids or salts thereof |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
DK0985039T3 (da) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
EP1001968B1 (en) | 1997-06-13 | 2004-12-22 | Gryphon Therapeutics, Inc. | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
EP0885571B1 (de) * | 1997-06-21 | 2003-08-27 | Tesa AG | Klebfolienstreifen-Verbund und seine Verwendung |
US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
IL137178A0 (en) | 1998-01-23 | 2001-07-24 | Immunex Corp | Il-18 receptors |
EP1060194A1 (en) | 1998-02-25 | 2000-12-20 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6008321A (en) | 1998-03-16 | 1999-12-28 | Pharmacopeia, Inc. | Universal linker for combinatorial synthesis |
US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
CA2331607A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO1999059643A2 (en) * | 1998-05-20 | 1999-11-25 | Sdg, Inc. | Liposomal delivery complex |
US6355782B1 (en) | 1998-07-09 | 2002-03-12 | Baylor College Of Medicine | Hypohidrotic ectodermal dyplasia genes and proteins |
WO2000004148A1 (en) | 1998-07-15 | 2000-01-27 | Genentech, Inc. | Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia |
DE69911793T2 (de) * | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
WO2000018881A2 (en) * | 1998-09-30 | 2000-04-06 | New England Biolabs, Inc. | Intein mediated peptide ligation |
US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
AU773891C (en) * | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000028065A1 (en) | 1998-11-06 | 2000-05-18 | Novo Nordisk A/S | Method for the production of fvii |
US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
DK1141015T3 (da) | 1999-01-06 | 2010-01-25 | Genentech Inc | Insulin-lignende vækstfaktor (IGF) I-mutantvarianter |
ATE284415T1 (de) | 1999-01-06 | 2004-12-15 | Genentech Inc | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
CA2270600A1 (en) * | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
KR20020018197A (ko) * | 1999-05-19 | 2002-03-07 | 추후보정 | Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
DE60039240D1 (de) * | 1999-07-01 | 2008-07-31 | Univ Yale | Neovaskulär gerichtete immunkonjugate |
JP2003505020A (ja) | 1999-07-02 | 2003-02-12 | ジェネンテック・インコーポレーテッド | ペプチドリガンドドメイン及び多量体化ドメインを含む融合ペプチド |
AU781618C (en) * | 1999-07-02 | 2006-03-16 | Genentech Inc. | FVIIa antagonists |
US6469136B1 (en) | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
WO2001003737A1 (en) * | 1999-07-13 | 2001-01-18 | Bolder Biotechnology Inc. | Immunoglobulin fusion proteins |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
DK1200479T3 (da) * | 1999-08-09 | 2006-05-15 | Emd Lexigen Res Ct Corp | Multiple cytokin-antistof-komplekser |
CA2387545A1 (en) * | 1999-10-14 | 2001-04-19 | Human Genome Sciences, Inc. | Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
EP1230271A1 (en) | 1999-11-05 | 2002-08-14 | Biogen, Inc. | Hedgehog fusion proteins and uses |
US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
WO2001036637A1 (en) * | 1999-11-17 | 2001-05-25 | Immunex Corporation | Receptor activator of nf-kappa b |
DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
PL206148B1 (pl) | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
DE60117781T2 (de) * | 2000-04-21 | 2006-11-23 | Amgen Inc., Thousand Oaks | Peptidderivate des apolipoproteins-a1/aii |
DE10020332A1 (de) | 2000-04-26 | 2001-11-15 | Henkel Kgaa | Wasch- und Reinigungsmittel |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
WO2001083525A2 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
CN1318084C (zh) | 2000-05-26 | 2007-05-30 | 奥索-麦克尼尔药品公司 | 神经保护肽 |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
KR20030046389A (ko) | 2000-09-01 | 2003-06-12 | 그리폰 테라퓨틱스, 인코포레이티드 | 친핵체에 안정한 티오에스테르 발생 화합물, 제조 및 사용방법 |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
AU2002245204A1 (en) | 2000-10-25 | 2002-07-24 | Genzyme Corporation | Methods for treating blood coagulation disorders |
US7405276B2 (en) * | 2000-11-01 | 2008-07-29 | Elusys Therapeutics, Inc. | Method of producing bispecific molecules by protein trans-splicing |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
US20040132971A1 (en) * | 2001-02-09 | 2004-07-08 | Haaning Jesper Mortensen | Rank ligand-binding polypeptides |
CA2438628A1 (en) * | 2001-02-19 | 2002-08-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Artificial proteins with reduced immunogenicity |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
WO2002089828A2 (en) | 2001-05-04 | 2002-11-14 | Institute Of Molecular And Cell Biology | Interferons in the treatment of ischemia |
US7419949B2 (en) | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
US7144380B2 (en) * | 2001-07-23 | 2006-12-05 | Gilliam Larry A | Traction method and device |
ATE313693T1 (de) | 2001-08-31 | 2006-01-15 | Lille Zeger De | Bohrvorrichtung |
EP1300419B1 (en) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
US20030078180A1 (en) * | 2001-10-24 | 2003-04-24 | Benchmark Research & Technology, Inc. | Contaminant-tolerant foaming additive |
DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20030180287A1 (en) * | 2002-02-27 | 2003-09-25 | Immunex Corporation | Polypeptide formulation |
JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CN101143221A (zh) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
CA2491567A1 (en) | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
JP2006513139A (ja) | 2002-07-03 | 2006-04-20 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療薬の全身性送達のための中央部気道投与 |
EP1523504A2 (en) | 2002-07-12 | 2005-04-20 | Novo Nordisk A/S | A tissue factor binding immunoconjugate comprising factor viia |
US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
SI1562972T1 (sl) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20050037947A1 (en) | 2003-05-06 | 2005-02-17 | Bitonti Alan J. | Inhibition of drug binding to serum albumin |
US20050281829A1 (en) | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
PL2077121T3 (pl) | 2003-05-06 | 2011-07-29 | Syntonix Pharmaceuticals Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego |
DK1641483T3 (da) | 2003-06-12 | 2008-06-02 | Lilly Co Eli | Fusionsproteiner |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
CA2544865C (en) | 2003-11-05 | 2019-07-09 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
CA2546580A1 (en) | 2003-11-18 | 2005-06-09 | Iconic Therapeutics, Inc. | Homogeneous preparations of chimeric proteins |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
KR101149242B1 (ko) | 2004-01-12 | 2012-05-25 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | Fc 영역 변이체 |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
DK1773872T3 (en) | 2004-05-21 | 2017-05-08 | Uab Res Found | VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006019447A1 (en) | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US7427787B2 (en) | 2005-07-08 | 2008-09-23 | Texas Instruments Incorporated | Guardringed SCR ESD protection |
US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
BRPI0709598A8 (pt) | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | composições de polipeptídeos estabilizados |
EP2650305B1 (en) * | 2006-03-24 | 2024-05-08 | Bioverativ Therapeutics Inc. | PC5 as a factor IX propeptide processing enzyme |
JP5800458B2 (ja) | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
EP1952822A1 (en) | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
WO2009053368A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
KR101841870B1 (ko) | 2008-05-16 | 2018-03-23 | 바이엘 헬스케어 엘엘씨 | 표적화 응고 인자 및 그의 사용 방법 |
JP5770161B2 (ja) | 2009-04-06 | 2015-08-26 | ノヴォ ノルディスク アー/エス | 血小板への第viii因子タンパク質の標的送達 |
EP2445513B1 (en) | 2009-06-25 | 2014-08-27 | The University of North Carolina At Chapel Hill | Chimeric factor vii molecules |
ES2898683T3 (es) | 2009-08-27 | 2022-03-08 | Novo Nordisk As | Direccionamiento del factor tisular a las plaquetas activadas |
SG181130A1 (en) | 2009-12-06 | 2012-07-30 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
MX356527B (es) * | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
US9611310B2 (en) * | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
BR112013021661A2 (pt) | 2011-03-02 | 2016-11-22 | Novo Nordisk As | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas |
-
2004
- 2004-05-05 TW TW093112725A patent/TWI353991B/zh active
- 2004-05-06 CN CN201410443460.1A patent/CN104448003B/zh not_active Expired - Lifetime
- 2004-05-06 HU HUE10182890A patent/HUE030293T2/en unknown
- 2004-05-06 JP JP2006532807A patent/JP5091480B2/ja not_active Expired - Lifetime
- 2004-05-06 PT PT101828903T patent/PT2361932T/pt unknown
- 2004-05-06 SI SI200432336A patent/SI2361932T1/sl unknown
- 2004-05-06 AU AU2004252422A patent/AU2004252422B2/en active Active
- 2004-05-06 DK DK10182902.6T patent/DK2357196T3/en active
- 2004-05-06 EP EP04775946.9A patent/EP1625209B1/en not_active Expired - Lifetime
- 2004-05-06 EP EP21191566.5A patent/EP3978508A1/en not_active Withdrawn
- 2004-05-06 CN CN2004800191889A patent/CN1852736B/zh not_active Expired - Lifetime
- 2004-05-06 SI SI200432348A patent/SI2174946T1/sl unknown
- 2004-05-06 PT PT47759469T patent/PT1625209E/pt unknown
- 2004-05-06 ES ES10182902.6T patent/ES2579938T3/es not_active Expired - Lifetime
- 2004-05-06 SI SI200432335A patent/SI2357196T1/sl unknown
- 2004-05-06 HU HUE09013214A patent/HUE031663T2/en unknown
- 2004-05-06 ES ES10182890.3T patent/ES2582947T3/es not_active Expired - Lifetime
- 2004-05-06 EP EP09013214.3A patent/EP2174946B1/en not_active Expired - Lifetime
- 2004-05-06 EP EP10182902.6A patent/EP2357196B9/en not_active Expired - Lifetime
- 2004-05-06 EP EP10182890.3A patent/EP2361932B2/en not_active Expired - Lifetime
- 2004-05-06 EA EA200501756A patent/EA012566B1/ru not_active IP Right Cessation
- 2004-05-06 US US10/841,250 patent/US7404956B2/en active Active
- 2004-05-06 WO PCT/US2004/013939 patent/WO2004101739A2/en active Search and Examination
- 2004-05-06 PL PL04775946T patent/PL1625209T3/pl unknown
- 2004-05-06 DK DK09013214.3T patent/DK2174946T3/en active
- 2004-05-06 AT AT04751356T patent/ATE446307T1/de not_active IP Right Cessation
- 2004-05-06 CA CA2522590A patent/CA2522590C/en not_active Expired - Lifetime
- 2004-05-06 ES ES04775946T patent/ES2431116T3/es not_active Expired - Lifetime
- 2004-05-06 BR BR122019011535-4A patent/BR122019011535B1/pt active IP Right Grant
- 2004-05-06 HU HUE10182902A patent/HUE030065T2/en unknown
- 2004-05-06 SI SI200432097T patent/SI1625209T1/sl unknown
- 2004-05-06 WO PCT/US2004/014064 patent/WO2005001025A2/en active Application Filing
- 2004-05-06 PL PL10182902.6T patent/PL2357196T3/pl unknown
- 2004-05-06 DK DK04775946.9T patent/DK1625209T3/da active
- 2004-05-06 DK DK10182890.3T patent/DK2361932T3/en active
- 2004-05-06 EP EP04751356A patent/EP1654378B1/en not_active Expired - Lifetime
- 2004-05-06 US US10/842,054 patent/US7381408B2/en active Active
- 2004-05-06 PT PT101829026T patent/PT2357196T/pt unknown
- 2004-05-06 UA UAA200511543A patent/UA95436C2/uk unknown
- 2004-05-06 CN CN201110082150.8A patent/CN102234334B/zh not_active Expired - Lifetime
- 2004-05-06 EP EP16167345.4A patent/EP3103809B1/en not_active Expired - Lifetime
- 2004-05-06 PL PL10182890.3T patent/PL2361932T3/pl unknown
- 2004-05-06 DE DE602004023724T patent/DE602004023724D1/de not_active Expired - Lifetime
- 2004-05-06 BR BRPI0410345A patent/BRPI0410345A8/pt not_active Application Discontinuation
-
2005
- 2005-11-03 IL IL171779A patent/IL171779A/en active Protection Beyond IP Right Term
- 2005-12-06 NO NO20055773A patent/NO339539B1/no active Protection Beyond IP Right Term
-
2006
- 2006-08-11 HK HK11113913.4A patent/HK1159649A1/zh not_active IP Right Cessation
- 2006-08-11 HK HK12101713.0A patent/HK1161604A1/zh not_active IP Right Cessation
- 2006-10-27 US US11/588,431 patent/US7862820B2/en active Active
-
2008
- 2008-04-09 US US12/100,183 patent/US7820162B2/en not_active Expired - Lifetime
-
2010
- 2010-05-16 IL IL205802A patent/IL205802A/en active Protection Beyond IP Right Term
- 2010-10-22 US US12/910,265 patent/US20110159540A1/en not_active Abandoned
- 2010-11-23 US US12/952,551 patent/US8329182B2/en not_active Expired - Lifetime
-
2012
- 2012-01-10 JP JP2012002429A patent/JP2012067142A/ja active Pending
- 2012-11-02 US US13/667,951 patent/US8932830B2/en not_active Expired - Lifetime
-
2013
- 2013-10-16 CY CY20131100911T patent/CY1114639T1/el unknown
-
2014
- 2014-04-28 JP JP2014092357A patent/JP2014139244A/ja not_active Withdrawn
- 2014-10-31 US US14/530,256 patent/US9636416B2/en not_active Expired - Lifetime
-
2015
- 2015-12-02 JP JP2015235339A patent/JP2016034977A/ja active Pending
-
2016
- 2016-03-08 HU HUS1600011C patent/HUS1600011I1/hu unknown
- 2016-03-09 NL NL300799C patent/NL300799I2/nl unknown
- 2016-03-09 LU LU92991C patent/LU92991I2/xx unknown
- 2016-03-15 FR FR16C0011C patent/FR16C0011I2/fr active Active
- 2016-03-17 LT LTPA2016007C patent/LTC1625209I2/lt unknown
- 2016-03-18 CY CY2016007C patent/CY2016007I1/el unknown
- 2016-03-22 NO NO20160483A patent/NO342384B1/no unknown
- 2016-04-06 BE BE2016C015C patent/BE2016C015I2/fr unknown
- 2016-07-11 CY CY20161100651T patent/CY1117756T1/el unknown
- 2016-07-11 CY CY20161100653T patent/CY1117764T1/el unknown
- 2016-10-18 LT LTPA2016028C patent/LTPA2016028I1/lt unknown
-
2017
- 2017-03-21 US US15/465,319 patent/US11401322B2/en not_active Expired - Lifetime
- 2017-04-19 US US15/491,742 patent/US9725496B1/en not_active Expired - Lifetime
- 2017-06-23 NO NO2017028C patent/NO2017028I2/no unknown
- 2017-06-23 NO NO2017027C patent/NO2017027I2/no unknown
- 2017-10-06 JP JP2017195992A patent/JP6441432B2/ja not_active Expired - Lifetime
-
2018
- 2018-04-10 JP JP2018075260A patent/JP6526281B2/ja not_active Expired - Lifetime
-
2019
- 2019-07-22 US US16/518,642 patent/US11168125B2/en active Active
-
2020
- 2020-06-12 NO NO2020016C patent/NO2020016I1/no unknown
-
2021
- 2021-09-21 US US17/480,984 patent/US20220010000A1/en not_active Abandoned
-
2022
- 2022-06-02 US US17/830,745 patent/US20230023927A1/en active Pending